LLY

914.01

+1.22%↑

JNJ

235.73

+0.11%↑

ABBV

205.66

+0.7%↑

NVS

148.79

+1.99%↑

AZN

185.14

+0.97%↑

LLY

914.01

+1.22%↑

JNJ

235.73

+0.11%↑

ABBV

205.66

+0.7%↑

NVS

148.79

+1.99%↑

AZN

185.14

+0.97%↑

LLY

914.01

+1.22%↑

JNJ

235.73

+0.11%↑

ABBV

205.66

+0.7%↑

NVS

148.79

+1.99%↑

AZN

185.14

+0.97%↑

LLY

914.01

+1.22%↑

JNJ

235.73

+0.11%↑

ABBV

205.66

+0.7%↑

NVS

148.79

+1.99%↑

AZN

185.14

+0.97%↑

LLY

914.01

+1.22%↑

JNJ

235.73

+0.11%↑

ABBV

205.66

+0.7%↑

NVS

148.79

+1.99%↑

AZN

185.14

+0.97%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Отворен

1.3 2.36

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.27

Максимум

1.3

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	171
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+106.98% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-615K 80M
Предишно отваряне	-1.06
Предишно затваряне	1.3

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.03.2026 г., 23:50 ч. UTC

Пазарно говорене

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

22.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22.03.2026 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22.03.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22.03.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22.03.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Participated in Aurum Resources Equity Raising

22.03.2026 г., 22:54 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22.03.2026 г., 22:22 ч. UTC

Пазарно говорене

Значими събития в новините

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Значими събития в новините

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22.03.2026 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22.03.2026 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22.03.2026 г., 21:21 ч. UTC

Пазарно говорене

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22.03.2026 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

106.98% нагоре

12-месечна прогноза

Среден 2.67 USD 106.98%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.